Loading...

TARGETING UNMET GLOBAL NEEDS IN MULTI-BILLION DOLLAR MARKETS

review our transforming drug-delivery platforms

Virpax® Pharmaceuticals Inc., (Nasdaq: VRPX) is a specialty pharmaceutical company focused on pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur may extend local anesthetic at the wound/incision site, effectively managing post-operative pain for 96 hours as evidenced by non-clinical study data.

Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense, we are committed to developing non-addictive treatments. Additionally, our involvement in the Epilepsy Therapy Screening Program (ETSP) underscores our dedication to addressing drug-resistant epilepsy and rare diseases.

With a focus on optimizing non-addictive medications, our drug delivery platforms target unmet global needs in markets such as Post Operative Pain, Severe Pain, Post Cancer Pain, and Rare Pediatric Epilepsy, including orphan diseases like Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome. Virpax is at the forefront of providing differentiated solutions for these diverse healthcare challenges.

Virpax is traded on

(Nasdaq: VRPX)

View our presentation

OPTIMIZING NON-ADDICTIVE DRUG DELIVERY

IN THE MANAGEMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES

Probudur injection icon

Probudur™
Lead Product Candidate

Injectable liposomal Bupivacaine

Probudur is a next generation liposomal bupivacaine formulation that has demonstrated 96 hours pain control after administering a single injection at the wound site in animal studies.

Probudur injection icon

Probudur™ Lead Product Candidate

Injectable liposomal Bupivacaine

Probudur is a next generation liposomal bupivacaine formulation that has demonstrated 96 hours pain control after administering a single injection at the wound site in animal studies.

Envelta spray icon

Envelta™

Molecular Envelope Enkephalin Powder

Envelta is an innovative intranasal enkephalin powder formulation that has demonstrated an ability to control severe pain without exhibiting respiratory depression, drug seeking behavior and drug tolerance in animal studies compared to morphine.

VRP324 spray icon

NobrXiol™

Molecular Envelope Cannabidiol Powder

NobrXiol is an innovative pharmaceutical-grade cannabidiol intranasal dry powder spray being developed to manage Rare Pediatric Epilepsy that bypasses the blood brain barrier and avoids drug to drug interactions seen in approved oral formulations.

Virpax is positioning its proprietary Rx pipeline to meet unmet needs in

three multi-billion dollar markets

OUR MISSION

Our purpose is to develop innovative delivery platform technologies that optimize patient care worldwide in non-addictive pain and neurological disorders.

OUR VISION

We aspire to be a leader in addressing patient and provider needs worldwide in the management of pain and neurological disorders.

“We’ve continued to support development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices.”

ROBERT CALIFF

FDA Commissioner
ADVANCINGNON-ADDICTIVEPAIN MANAGEMENTWORLDWIDE

Experienced

executive leadership

Robust

pipeline